Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer

Journal of Medical Genetics

Volumn 53, Issue 7, 2016, Pages 465-471

  Kast, Karin ^a,b   Rhiem, Kerstin ^c   Wappenschmidt, Barbara ^c   Hahnen, Eric ^c   Hauke, Jan ^c   Bluemcke, Britta ^c   Zarghooni, Verena ^c   Herold, Natalie ^c   Ditsch, Nina ^d   Kiechle, Marion ^e   Braun, Michael ^f   Fischer, Christine ^g   Dikow, Nicola ^g   Schott, Sarah ^b,h   Rahner, Nils ⁱ   Niederacher, Dieter ⁱ   Fehm, Tanja ⁱ   Gehrig, Andrea ^j   Mueller Reible, Clemens ^j   Arnold, Norbert ^k   Maass, Nicolai ^k   Borck, Guntram ^l   de Gregorio, Nikolaus ^m   Scholz, Caroline ⁿ   Auber, Bernd ⁿ   Varon Manteeva, Raymonda ^o   Speiser, Dorothee ^o   Horvath, Judit ^p   Lichey, Nadine ^p   Wimberger, Pauline ^a,b   Stark, Sylvia ^q   Faust, Ulrike ^r   Weber, Bernhard H F ^s   Emons, Gunter ^t   Zachariae, Silke ^q   Meindl, Alfons ^e   Schmutzler, Rita K ^c   Engel, Christoph ^q   more..

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f Gynecological Hospital Red Cross   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ Department of Orthopedic Surgery   (Germany)

^j UNIVERSITY OF WÜRZBURG   (Germany)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^l UNIVERSITY OF ULM   (Germany)

^m UNIVERSITY HOSPITAL ULM   (Germany)

ⁿ HANNOVER MEDICAL SCHOOL   (Germany)

^o CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^p UNIVERSITY OF MÜNSTER   (Germany)

^q UNIVERSITY OF LEIPZIG   (Germany)

^r UNIVERSITY OF TÜBINGEN   (Germany)

^s UNIVERSITY OF REGENSBURG   (Germany)

^t UNIVERSITY OF GÖTTINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER SCREENING; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; FAMILIAL CANCER; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE BREAST CANCER; MIDDLE AGED; MOLECULAR PATHOLOGY; MUTATION RATE; OVARY CANCER; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; OVARY TUMOR; PROCEDURES;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PREVALENCE;

EID: 84960896989     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2015-103672     Document Type: Article

References (34)

1. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
2. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994;73:643-51.
3. Fishman A, Dekel E, Chetrit A, Lerner-Geva L, Bar-Am A, Beck D, Beller U, Ben-Baruch G, Piura B, Friedman E, Struewing JP, Modan B. Patients with double primary tumors in the breast and ovary-clinical characteristics and BRCA1-2 mutations status. Gynecol Oncol 2000;79:74-8.
4. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, and the Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
5. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science (New York, NY) 1990;250:1684-9.
6. Meindl A, Ditsch N, Kast K, Rhiem K, Schmutzler RK. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int 2011;108:323-30.
7. Kreienberg R, Albert U, Follmann M, Kopp I, Kühn T, Wöckel A. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Senologie-Zeitschrift für Mammadiagnostik und-therapie 2013;10:164-92.
8. Familial Breast Cancer. Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. Cardiff, UK: National Collaborating Centre for Cancer, 2013.
9. Capalbo C, Ricevuto E, Vestri A, Ristori E, Sidoni T, Buffone O, Adamo B, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models. Ann Oncol 2006;17(Suppl 7):vii34-40.
10. Claes K, Poppe B, Coene I, Paepe AD, Messiaen L. BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. Br J Cancer 2004;90:1244-51.
11. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-90.
12. Machackova E, Foretova L, Lukesova M, Vasickova P, Navratilova M, Coene I, Pavlu H, Kosinova V, Kuklova J, Claes K. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. BMC Cancer 2008;8:140.
13. Menkiszak J, Gronwald J, Gorski B, Jakubowska A, Huzarski T, Byrski T, Foszczynska-Kloda M, Haus O, Janiszewska H, Perkowska M, Brozek I, Grzybowska E, Zientek H, Gozdz S, Kozak-Klonowska B, Urbanski K, Miturski R, Kowalczyk J, Pluzanska A, Niepsuj S, Koc J, Szwiec M, Drosik K, Mackiewicz A, Lamperska K, Strozyk E, Godlewski D, Stawicka M, Wasko B, Bebenek M, Rozmiarek A, Rzepka-Gorska I, Narod SA, Lubinski J. Hereditary ovarian cancer in Poland. Int J Cancer 2003;106:942-5.
14. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-706.
15. Arnold N, Gross E, Schwarz-Boeger U, Pfisterer J, Jonat W, Kiechle M. A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers. Hum Mutat 1999;14:333-9.
16. Gross E, Arnold N, Pfeifer K, Bandick K, Kiechle M. Identification of specific BRCA1 and BRCA2 variants by DHPLC. Hum Mutat 2000;16:345-53.
17. Eccles DM, Mitchell G, Monteiro AN, Schmutzler R, Couch FJ, Spurdle AB, Gómez-García EB; ENIGMA Clinical Working Group. BRCA1 and BRCA2 genetic testingpitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol 2015;26:2057-65.
18. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV; IARC Unclassified Genetic Variants Working Group. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008;29:1282-91.
19. Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, Radice P, Stoppa-Lyonnet D, Tavtigian S, Wappenschmidt B, Couch FJ, Goldgar DE. ENIGMA-evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat 2012;33:2-7.
20. Kast K, Schmutzler RK, Rhiem K, Kiechle M, Fischer C, Niederacher D, Arnold N, Grimm T, Speiser D, Schlegelberger B, Varga D, Horvath J, Beer M, Briest S, Meindl A, Engel C. Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. Int J Cancer 2014;135:2352-61.
21. Gershoni-Baruch R, Dagan E, Fried G, Kepten I, Robinson E. BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. Eur J Hum Genet 1999;7:833-6.
22. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409-15.
23. Evans DG, Ahmed M, Bayliss S, Howard E, Lalloo F, Wallace A. BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/ or ovaries. J Med Genet 2010;47:561-6.
24. Steinmann D, Bremer M, Rades D, Skawran B, Siebrands C, Karstens JH, Dork T. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. Br J Cancer 2001;85:850-8.
25. FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber DA. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996;334:143-9.
26. Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 1996;334:137-42.
27. Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Pelttari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015;33:304-11.
28. Chen S, Wang W, Broman KW, Katki HA, Parmigiani G. BayesMendel: an R environment for Mendelian risk prediction. Stat Appl Genet Mol Biol 2004;3:Article21.
29. Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer 2014;110:535-45.
30. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-30.
31. Fischer C, Kuchenbacker K, Engel C, Zachariae S, Rhiem K, Meindl A, Rahner N, Dikow N, Plendl H, Debatin I, Grimm T, Gadzicki D, Flottmann R, Horvath J, Schrock E, Stock F, Schafer D, Schwaab I, Kartsonaki C, Mavaddat N, Schlegelberger B, Antoniou AC, Schmutzler R, German Consortium for Hereditary Breast and Ovarian Cancer. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. J Med Genet 2013;50:360-7.
32. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, McGuffog L, Steele D, Devilee P, Klijn JG, Meijers-Heijboer H, Radice P, Pilotti S, Nevanlinna H, Butzow R, Sobol H, Jacquemier J, Lyonet DS, Neuhausen SL, Weber B, Wagner T, Winqvist R, Bignon YJ, Monti F, Schmitt F, Lenoir G, Seitz S, Hamman U, Pharoah P, Lane G, Ponder B, Bishop DT, Easton DF. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004;10:2473-81.
33. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 2009;40:1213-23.
34. Prat J, Ribe A, Gallardo A. Hereditary ovarian cancer. Hum Pathol 2005;36: 861-70.